Abstract
Moderate-strong CYP3A4 or Pgp inhibitors and inducers alter direct oral anticoagulant (DOAC) pharmacokinetics. Whether the presence of a DOAC drug-drug interaction (DDI) prompts in- hospital changes in management remains unknown. We identified all hospitalized patients at our institution who were admitted with a clinically relevant DOAC DDI from 01/2021 to 06/2021. Clinically relevant DOAC DDIs were defined as those listed in the prescribing information or FDA CYP3A4/Pgp inhibitors clinical indexes. We assessed the prevalence of DOAC DDIs and categorized their management as: drug stopped, drug held, or drug continued. For drugs that were continued we assessed whether the dose of the DOAC or interacting drug was increased, decreased or unchanged during the admission. We ascertained the number of DOAC DDIs that prompted an automated prescribing alert in our electronic health record (EHR). Finally, we conducted a logistic regression model to compare users of DOACs with DDI who had their regimen adjusted versus those without adjustments, focusing on outcomes of rehospitalization and death, adjusting for age and gender. Among 3,725 hospitalizations with a DOAC admission order, 197 (5%) had a clinically relevant DOAC DDI. The DOAC and the interacting drug were continued at discharge for 124 (63%) hospitalizations. The most frequent adjustments were stopping the interacting drug (73%) and stopping the DOAC (15%). Only 7 (4%) of DOAC DDIs prompted an EHR alert. The adjusted odds ratios for rehospitalizations and death, respectively, among patients whose regimens were adjusted compared to those whose were not, were 1.29 (95% CI, 0.67 to 2.48; P = 0.44) and 1.88 (95% CI, 0.91 to 3.89; P = 0.09). Clinically relevant DDIs with DOACs occur infrequently among hospitalized patients and usually are managed without stopping the DOAC. The clinical impact of such DDIs and subsequent adjustments on thrombotic and hemorrhagic outcomes requires further investigation.
Similar content being viewed by others
References
Forbes HL, Polasek TM (2017) Potential drug-drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Safe 8(10):319–328. https://doi.org/10.1177/2042098617719815
Kaaber AB, Jans Ø, Dziegiel MH, Stensballe J, Johansson PI (2021) Managing patients on direct factor Xa inhibitors with rapid thrombelastography. Scand J Clin Lab Invest 81(8):661–669. https://doi.org/10.1080/00365513.2021.2003855
Information P (2015) ELIQUIS(R) oral tablets, apixaban oral tablets. Bristol-Myers Squibb Company and Pfizer Inc (per FDA), Princeton, NJ
‘Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2021
Product Information: SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi Sankyo, Inc. (per FDA), Parsippany, NJ, 2015.
Information P (2019) XARELTO(R) oral tablets, rivaroxaban oral tablets. NJ, Janssen Pharmaceuticals Inc (per FDA), Titusville
Drug database: Medication decision support. FDB (First Databank). (n.d.). https://www.fdbhealth.com. Accessed 15 Oct 2023
Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll G, McArthur E, Sood MM (2020) Risk of Hospitalization With Hemorrhage Among Older Adults Taking Clarithromycin vs Azithromycin and Direct Oral Anticoagulants. JAMA Intern Med 180(8):1052–1060. https://doi.org/10.1001/jamainternmed.2020.1835
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Al Zaria, M.H., Buckley, L.F., Dell’orfano, H. et al. Management of direct oral anticoagulant drug interactions in hospitalized patients. J Thromb Thrombolysis 57, 598–602 (2024). https://doi.org/10.1007/s11239-024-02967-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-024-02967-2